Skip to main content

Advertisement

SpringerLink
Log in

Is BEACOPP better than ABVD?

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

The majority of patients with advanced Hodgkin’s lymphoma are cured with currently available therapy, such as ABVD (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine). However, almost 20% of patients fail to achieve a complete remission and almost 40% relapse with prolonged follow-up. BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) was developed by the German Hodgkin’s Study Group to improve on standard therapy by intensifying treatment and substituting the active agent etoposide for vinblastine and dacarbazine. Promising results led to the HD9 trial, in which escalated BEACOPP was superior to COPP/ABVD (cyclophosphamide, vincristine, prednisone, procarbazine/ABVD). Nevertheless, escalated BEACOPP is myelosuppressive and is associated with an increased risk of secondary malignancies. Modifications of BEACOPP have been developed in an attempt to increase efficacy and reduce the adverse effects. Whether BEACOPP should be selected in preference to ABVD may be determined by clinical stage, patient age, and other risk factors. The answer to whether escalated BEACOPP is superior to ABVD will require the results of an ongoing randomized trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. DeVita VT Jr, Serpick AA: Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 1970, 73:881–895.

    PubMed  Google Scholar 

  2. DeVita VT Jr, Simon RM, Hubbard SM, et al.: Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587–595.

    PubMed  Google Scholar 

  3. Santoro A, Bonfante V, Bonadonna G: Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin’s disease. Ann Intern Med 1982, 96:139–143.

    PubMed  CAS  Google Scholar 

  4. Bonadonna G, Zucali R, Monfardini S, et al.: Combination chemotherapy of Hodgkin’s disease with Adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252–259.

    Article  PubMed  CAS  Google Scholar 

  5. Santoro A, Bonadonna G, Bonfante V, Valagussa P: Alternating drug combinations in the treatment of advanced Hodgkin’s disease. N Engl J Med 1982, 306:770–775.

    Article  PubMed  CAS  Google Scholar 

  6. Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478–1484.

    Article  PubMed  CAS  Google Scholar 

  7. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 1986, 104:739–746.

    PubMed  CAS  Google Scholar 

  8. Klimo P, Connors JM: MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin’s disease. J Clin Oncol 1985, 3:1174–1182.

    PubMed  CAS  Google Scholar 

  9. Glick JH, Young ML, Harrington D, et al.: MOPP/ABV hybrid chemotherapy for advanced Hodgkin’s disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol 1998, 16:19–26.

    PubMed  CAS  Google Scholar 

  10. Duggan DB, Petroni GR, Johnson JL, et al.: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 2003, 21:607–614.

    Article  PubMed  CAS  Google Scholar 

  11. Diehl V, Sieber M, Rüffer U, et al.: BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin’s disease. Ann Oncol 1997, 8:143–148.

    Article  PubMed  CAS  Google Scholar 

  12. Tesch H, Diehl V, Lathan B, et al.: Moderate dose escalation for advanced stage Hodgkin’s disease using the bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin’s Lymphoma Study Group. Blood 1998, 92:4560–4567.

    PubMed  CAS  Google Scholar 

  13. Diehl V, Franklin J, Pfreundschuh M, et al.: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 2003, 348:2386–2395.

    Article  PubMed  CAS  Google Scholar 

  14. Rüffer JU, Ballova V, Glossman J, et al.: BEACOPP and COPP/ABVD as salvage treatments after primary extended field radiation therapy of early stage Hodgkin’s disease—results of the German Hodgkin Study Group. Leuk Lymph 2005, 46:1561–1567.

    Article  Google Scholar 

  15. Dann EJ, Bar-Shalom R, Tamir A, et al.: Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007, 109:905–909.

    Article  PubMed  CAS  Google Scholar 

  16. Behringer K, Breuer K, Reineke T, et al.: Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2005, 23:7555–7564.

    Article  PubMed  Google Scholar 

  17. Josting A, Wiedenmann S, Franklin J, et al.: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003, 21:3440–3446.

    Article  PubMed  Google Scholar 

  18. Behringer K, Josting A, Schiller P, et al.: Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004, 15:1079–1085.

    Article  PubMed  CAS  Google Scholar 

  19. Sieber M, Bredenfield H, Josting A, et al.: 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin’s lymphoma: results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2003, 21:1734–1739.

    Article  PubMed  CAS  Google Scholar 

  20. Engert A, Bredenfield H, Döhner H, et al.: Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin’s lymphoma: results of a phase II study. Haematologica 2006, 91:546–549.

    PubMed  CAS  Google Scholar 

  21. Engert A, Franklin J, Mueller RP, et al.: HD12 randomized trial comparing 8 dose-escalated cycles of BEACOPP with 4 escalated and 4 baseline cycles in patients with advanced stage Hodgkin lymphoma (HL): an analysis of the German Hodgkin Lymphoma Study Group (GHSG) [abstract]. Blood 2006, 108(pt 1):33a (Abstract 99).

    Google Scholar 

  22. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998, 339:1506–1514.

    Article  PubMed  CAS  Google Scholar 

  23. Ballova V, Rüffer J-U, Haverkamp H, et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005, 16:124–131.

    Article  PubMed  CAS  Google Scholar 

  24. Hartmann P, Rehwald U, Salzberger B, et al.: BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Ann Oncol 2003, 14:1562–1569.

    Article  PubMed  CAS  Google Scholar 

  25. Canellos GP, Duggan D, Johnson J, Niedzwiecki D: How important is bleomycin in the Adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 2004, 22:1532–1533.

    Article  PubMed  Google Scholar 

  26. Martin WG, Ristow KM, Habermann TM, et al.: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005, 23:7614–7620.

    Article  PubMed  CAS  Google Scholar 

  27. Santoro A, Devizzi L, Bonfante V, et al.: Phase II study with gemcitabine in pretreated patients with Hodgkin’s (HD) and non-Hodgkin’s lymphomas (NHL): results of a multicenter study [abstract]. Proc Am Soc Clin Oncol 1997, 16:21a (Abstract 71).

    Google Scholar 

  28. Tesch H, Santoro A, Fiedler F, et al.: Phase II study of gemcitabine in pretreated Hodgkin’s disease: results of a multicenter study [abstract]. Blood 1997, 90(suppl 1):339a (Abstract 1514).

    Google Scholar 

  29. Bredenfield H, Franklin J, Nogova L, et al.: Severe pulmonary toxicity in patients with advanced-stage Hodgkin’s disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2004, 22:2424–2429.

    Article  CAS  Google Scholar 

  30. Friedberg JW, Neuberg D, Kim H, et al.: Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin’s disease: unacceptable acute pulmonary toxicity. Cancer 2003, 98:978–982.

    Article  PubMed  CAS  Google Scholar 

  31. Bartlett N, Niedzwiecki D, Johnson J, et al.: Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol 2007, In press.

  32. Hutchings M, Loft A, Hansen M, et al.: FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52–59.

    Article  PubMed  CAS  Google Scholar 

  33. Cheson BD, Pfistner B, Juweid ME, et al.: Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579–586.

    Article  PubMed  Google Scholar 

  34. Sanchez-Aguilera A, Montalban C, de la Cueva P, et al.: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006, 108:662–668.

    Article  PubMed  CAS  Google Scholar 

  35. Diehl V, Brillant C, Engert A, et al.: Recent interim analysis of the HD11 trial of the GHSG: intensification of chemotherapy and reduction of radiation dose in early unfavorable stage Hodgkin’s lymphoma [abstract]. Blood 2005, 106:816a.

    Google Scholar 

  36. Fuchs M, Diehl V, Re D: Current strategies and new approaches in the treatment of Hodgkin’s lymphoma [review]. Pathobiology 2006, 73:126–140.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Georgetown University Hospital, 3800 Reservoir Road, N.W., Washington, DC, 20007, USA

    Bruce D. Cheson MD

Authors
  1. Bruce D. Cheson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce D. Cheson MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheson, B.D. Is BEACOPP better than ABVD?. Curr Hematol Malig Rep 2, 161–166 (2007). https://doi.org/10.1007/s11899-007-0022-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0022-2

Keywords

Search

Navigation